Does the media prefer AXSM or JAZZ?

In the previous week, Jazz Pharmaceuticals had 4 more articles in the media than Axsome Therapeutics. MarketBeat recorded 10 mentions for Jazz Pharmaceuticals and 6 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.61 beat Jazz Pharmaceuticals' score of 0.27 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TAK or JAZZ?

Jazz Pharmaceuticals has a consensus price target of $289.37, suggesting a potential upside of 24.54%. Given Jazz Pharmaceuticals' higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Jazz Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media refer more to TAK or JAZZ?

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Jazz Pharmaceuticals and 3 mentions for Takeda Pharmaceutical. Jazz Pharmaceuticals' average media sentiment score of 0.27 beat Takeda Pharmaceutical's score of -0.26 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Jazz Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ONC or JAZZ?

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 10 mentions for Jazz Pharmaceuticals and 3 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.15 beat Jazz Pharmaceuticals' score of 0.27 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RPRX or JAZZ?

In the previous week, Royalty Pharma and Royalty Pharma both had 10 articles in the media. Royalty Pharma's average media sentiment score of 0.63 beat Jazz Pharmaceuticals' score of 0.27 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Jazz Pharmaceuticals (JAZZ) Competitors

$232.35 -5.93 (-2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$226.39 -5.96 (-2.57%)

As of 04:55 PM Eastern

Compare

JAZZ vs. AXSM, TAK, TEVA, ONC, and RPRX

Should you buy Jazz Pharmaceuticals stock or one of its competitors? Jazz Pharmaceuticals's main competitors and comparable companies include Axsome Therapeutics (AXSM), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Royalty Pharma (RPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Jazz Pharmaceuticals had 4 more articles in the media than Axsome Therapeutics. MarketBeat recorded 10 mentions for Jazz Pharmaceuticals and 6 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.61 beat Jazz Pharmaceuticals' score of 0.27 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	15.27	-$183.17M	-$3.75	N/A
Jazz Pharmaceuticals	$4.27B	3.53	-$356.15M	$14.50	16.02

Axsome Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Axsome Therapeutics' net margin of -24.68%. Jazz Pharmaceuticals' return on equity of 33.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Axsome Therapeutics presently has a consensus target price of $271.00, indicating a potential upside of 45.59%. Jazz Pharmaceuticals has a consensus target price of $289.37, indicating a potential upside of 24.54%. Given Axsome Therapeutics' higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.86
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Jazz Pharmaceuticals has lower revenue, but higher earnings than Takeda Pharmaceutical. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.09	-$1.01B	$0.34	54.37
Jazz Pharmaceuticals	$4.27B	3.53	-$356.15M	$14.50	16.02

Jazz Pharmaceuticals has a consensus price target of $289.37, suggesting a potential upside of 24.54%. Given Jazz Pharmaceuticals' higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Jazz Pharmaceuticals and 3 mentions for Takeda Pharmaceutical. Jazz Pharmaceuticals' average media sentiment score of 0.27 beat Takeda Pharmaceutical's score of -0.26 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Takeda Pharmaceutical has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Takeda Pharmaceutical's net margin of 3.80%. Jazz Pharmaceuticals' return on equity of 33.97% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Summary

Jazz Pharmaceuticals beats Takeda Pharmaceutical on 13 of the 15 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Teva Pharmaceutical Industries has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

Teva Pharmaceutical Industries currently has a consensus price target of $43.73, indicating a potential upside of 9.75%. Jazz Pharmaceuticals has a consensus price target of $289.37, indicating a potential upside of 24.54%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00

Jazz Pharmaceuticals has a net margin of 20.45% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Jazz Pharmaceuticals' return on equity of 33.97% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Teva Pharmaceutical Industries has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.69	$1.41B	$0.60	66.40
Jazz Pharmaceuticals	$4.27B	3.53	-$356.15M	$14.50	16.02

In the previous week, Teva Pharmaceutical Industries had 16 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 10 mentions for Jazz Pharmaceuticals. Teva Pharmaceutical Industries' average media sentiment score of 0.51 beat Jazz Pharmaceuticals' score of 0.27 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	8 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Jazz Pharmaceuticals has a net margin of 20.45% compared to BeOne Medicines' net margin of 10.70%. Jazz Pharmaceuticals' return on equity of 33.97% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 10 mentions for Jazz Pharmaceuticals and 3 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.15 beat Jazz Pharmaceuticals' score of 0.27 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines currently has a consensus price target of $402.71, suggesting a potential upside of 10.25%. Jazz Pharmaceuticals has a consensus price target of $289.37, suggesting a potential upside of 24.54%. Given Jazz Pharmaceuticals' higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.06
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00

BeOne Medicines has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

BeOne Medicines has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.51	$286.93M	$5.68	64.31
Jazz Pharmaceuticals	$4.27B	3.53	-$356.15M	$14.50	16.02

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BeOne Medicines beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

In the previous week, Royalty Pharma and Royalty Pharma both had 10 articles in the media. Royalty Pharma's average media sentiment score of 0.63 beat Jazz Pharmaceuticals' score of 0.27 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Royalty Pharma has a net margin of 32.14% compared to Jazz Pharmaceuticals' net margin of 20.45%. Jazz Pharmaceuticals' return on equity of 33.97% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Royalty Pharma has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	14.08	$770.95M	$1.45	40.15
Jazz Pharmaceuticals	$4.27B	3.53	-$356.15M	$14.50	16.02

Royalty Pharma has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

Royalty Pharma presently has a consensus target price of $61.29, indicating a potential upside of 5.27%. Jazz Pharmaceuticals has a consensus target price of $289.37, indicating a potential upside of 24.54%. Given Jazz Pharmaceuticals' higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JAZZ vs. The Competition

Export

Metric	Jazz Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.08B	$12.53B	$7.26B	$13.03B
Dividend Yield	N/A	2.62%	2.52%	14.03%
P/E Ratio	16.02	789.85	274.72	25.67
Price / Sales	3.53	752.55	606.70	80.64
Price / Cash	14.63	15.22	28.02	35.00
Price / Book	3.27	10.59	10.49	6.43
Net Income	-$356.15M	$2.83B	$3.50B	$360.21M
7 Day Performance	-3.42%	-2.63%	-3.03%	-2.83%
1 Month Performance	-4.98%	-1.41%	-4.16%	-4.08%
1 Year Performance	80.09%	-0.33%	13.20%	3.84%

Jazz Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JAZZ Jazz Pharmaceuticals	4.2843 of 5 stars	$232.35 -2.5%	$289.37 +24.5%	+87.6%	$15.08B	$4.27B	16.02	2,890	Analyst Revision
AXSM Axsome Therapeutics	3.154 of 5 stars	$205.49 -1.1%	$267.60 +30.2%	+66.1%	$10.88B	$638.50M	N/A	925	Analyst Forecast
TAK Takeda Pharmaceutical	1.4515 of 5 stars	$18.91 flat	N/A	+28.2%	$60.59B	$28.32B	55.62	47,000
TEVA Teva Pharmaceutical Industries	3.1527 of 5 stars	$40.09 +2.8%	$43.10 +7.5%	+112.2%	$45.42B	$17.26B	66.82	33,950
ONC BeOne Medicines	3.5073 of 5 stars	$365.67 +4.2%	$402.71 +10.1%	+12.6%	$38.52B	$5.34B	64.38	12,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JAZZ) was last updated on 9/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, TAK, TEVA, ONC, and RPRX

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Takeda Pharmaceutical?

Summary

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Summary

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, TAK, TEVA, ONC, and RPRX

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Does the media prefer AXSM or JAZZ?

Which has preferable valuation and earnings, AXSM or JAZZ?

Which has more volatility and risk, AXSM or JAZZ?

Is AXSM or JAZZ more profitable?

Do analysts prefer AXSM or JAZZ?

Do institutionals & insiders believe in AXSM or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Takeda Pharmaceutical?

Which has higher valuation and earnings, TAK or JAZZ?

Do analysts prefer TAK or JAZZ?

Does the media refer more to TAK or JAZZ?

Which has more volatility & risk, TAK or JAZZ?

Do insiders and institutionals hold more shares of TAK or JAZZ?

Is TAK or JAZZ more profitable?

Summary

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Which has more volatility and risk, TEVA or JAZZ?

Do analysts recommend TEVA or JAZZ?

Is TEVA or JAZZ more profitable?

Which has preferable valuation & earnings, TEVA or JAZZ?

Does the media refer more to TEVA or JAZZ?

Do insiders and institutionals have more ownership in TEVA or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Is ONC or JAZZ more profitable?

Does the media favor ONC or JAZZ?

Do analysts recommend ONC or JAZZ?

Which has more volatility and risk, ONC or JAZZ?

Which has stronger valuation and earnings, ONC or JAZZ?

Do institutionals and insiders hold more shares of ONC or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Does the media favor RPRX or JAZZ?

Is RPRX or JAZZ more profitable?

Do institutionals and insiders have more ownership in RPRX or JAZZ?

Which has stronger earnings and valuation, RPRX or JAZZ?

Which has more risk & volatility, RPRX or JAZZ?

Do analysts rate RPRX or JAZZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools